Across TCGA pan-cancer cohorts, SPATA21 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated SPATA21 data layer compared with 3 for mutation status and 1 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPATA21 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA21 expression acts as an unfavorable survival marker, although some lineages such as LUAD and READ show a favorable association.
KIRC, ACC, and LUAD are the cancer types where SPATA21 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.